Ark Therapeutics Group PLC Manufacturing Partnership (4035I)
July 25 2012 - 2:00AM
UK Regulatory
TIDMAKT
RNS Number : 4035I
Ark Therapeutics Group PLC
25 July 2012
ARK THERAPEUTICS GROUP PLC
Ark Therapeutics enters manufacturing partnership with leading
European
gene therapy company
London, UK - 25 July 2012: Ark Therapeutics Group plc ("Ark") is
pleased to announce that it has signed a master manufacturing
services agreement with one of Europe's leading gene therapy
companies. The partnership will initially cover Ark's supply of
manufacturing and development services in respect of the partner's
therapeutic vaccine product. Financial details of the agreement
were not disclosed.
Dr David Venables, Ark's Executive Director of Manufacturing
commented: "We are delighted to announce this substantive
partnership which provides further validation of the strong
scientific and technological capabilities available at Ark, and the
progress we are making in building our strategy for viral focused
contract development and manufacturing services. As well as
providing state-of-the-art manufacturing capabilities, Ark is also
able to bring our partner the benefit of our own experience in
developing adenoviral based medicines."
For further information please contact:
Ark Therapeutics Group plc Tel: +44 (0)20 7388 7722
Iain Ross, Chairman Dr David Venables,
Executive Director of Manufacturing
FTI Consulting, Inc. Tel: +44 (0)20 7831 3113
Susan Stuart
Natalie Garland-Collins
Ark Therapeutics Group plc
Ark Therapeutics Group plc is a leading viral product focused
contract development and manufacturing services company with
world-class viral research, development and GMP manufacturing
operations in Finland and the UK. Ark's business model is to offer
product development and GMP manufacturing contract services for
viral products, including the areas of viral mediated gene therapy,
oncolytic viral vaccines, live and attenuated viral vaccines, viral
vectored vaccines and virus like particles. Ark's capabilities span
from translational research through preclinical and clinical
product development, in addition to process and analytical
development, GMP manufacture and sterile filling from pre-clinical
through to commercial product supply. These capabilities have been
established through the development of Ark's own products through
to Marketing Authorisation Application registered with the European
Medicines Agency. Following a change in business strategy in 2011,
Ark is now building its business through contract development and
manufacturing services and is seeking external partners to advance
its own product pipeline.
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's
financial position, business strategy, plans and objectives of
management for future operations (including development plans and
objectives relating to the Group's products and services), and any
statements preceded by, followed by or that include forward-looking
terminology such as the words "targets", "believes", "estimates",
"expects", "aims", "intends", "will", "can", "may", "anticipates",
"would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or
achievements of the Group to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are
based on numerous assumptions regarding the Group's present and
future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could
cause the Group's actual results, performance or achievements to
differ materially from those in forward-looking statements include
those relating to Ark's funding requirements, regulatory approvals,
clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements
speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained in this
announcement to reflect any change in the Group's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking
statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZZLFLLDFEBBX
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Oct 2023 to Oct 2024